Published in Lancet on February 25, 2009
Nighttime Valsartan in Hemodialysis Hypertension (NVHH) | NCT03594825
A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival. Kidney Int (2013) 2.23
Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. J Am Soc Nephrol (2010) 1.81
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int (2011) 1.74
Pro: Ambulatory blood pressure should be used in all patients on hemodialysis. Nephrol Dial Transplant (2015) 1.72
Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension (2014) 1.65
Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. Am J Kidney Dis (2009) 1.39
Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol (2010) 1.31
Urinary angiotensinogen is correlated with blood pressure in men (Bogalusa Heart Study). J Hypertens (2010) 1.18
Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol (2013) 1.17
Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2012) 1.15
Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol (2009) 1.09
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant (2014) 1.07
Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol (2014) 1.07
Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol (2010) 1.05
Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial (2010) 1.02
Successful treatment of hypertension in anuric hemodialysis patients with a direct Renin inhibitor, aliskiren. J Rural Med (2011) 0.98
Peridialytic, intradialytic, and interdialytic blood pressure measurement in hemodialysis patients. Am J Kidney Dis (2009) 0.97
Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. J Hum Hypertens (2010) 0.96
Pharmacotherapy of Hypertension in Chronic Dialysis Patients. Clin J Am Soc Nephrol (2016) 0.96
Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol (2010) 0.95
Managing hypertension using home blood pressure monitoring among haemodialysis patients--a call to action. Nephrol Dial Transplant (2010) 0.93
Systolic blood pressure and mortality in patients on hemodialysis. Curr Hypertens Rep (2011) 0.90
Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months. BMC Nephrol (2013) 0.87
A systematic review of the impact of center volume in dialysis. BMC Res Notes (2015) 0.86
Direct Renin inhibitor: aliskiren in chronic kidney disease. Nephrourol Mon (2012) 0.84
Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial. Trials (2012) 0.83
Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations. Pediatr Nephrol (2011) 0.83
Management of hypertension in the hemodialysis population: a review of the literature. J Community Hosp Intern Med Perspect (2014) 0.81
Interdialytic hypertension-an update. Adv Chronic Kidney Dis (2011) 0.81
Design of the Blood Pressure Goals in Dialysis pilot study. Am J Med Sci (2014) 0.81
The controversies of diagnosing and treating hypertension among hemodialysis patients. Semin Dial (2012) 0.81
Cardiovascular determinants of prognosis in normotensive hemodialysis patients. BMC Nephrol (2012) 0.80
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Ther Adv Chronic Dis (2011) 0.79
Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients. Int J Nephrol Renovasc Dis (2012) 0.79
Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients? Nutr J (2014) 0.79
Dietary patterns and clinical outcomes in hemodialysis patients in Japan: a cohort study. PLoS One (2015) 0.78
Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence. Br J Clin Pharmacol (2013) 0.78
Hypertension Treatment for Patients with Advanced Chronic Kidney Disease. Curr Cardiovasc Risk Rep (2014) 0.78
Can we reduce the cardiovascular risk in peritoneal dialysis patients? Indian J Nephrol (2010) 0.78
Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up. BMC Nephrol (2014) 0.78
Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy. World J Nephrol (2015) 0.78
Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials. Hemodial Int (2015) 0.78
Blood pressure and mortality: using offspring blood pressure as an instrument for own blood pressure in the HUNT study. Sci Rep (2015) 0.77
Prevalence of cardiovascular risk factors in hemodialysis patients - The CORDIAL study. Arq Bras Cardiol (2014) 0.77
Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol (2016) 0.76
Antihypertensive medication exposure and cardiovascular outcomes in hemodialysis patients. Am J Nephrol (2014) 0.76
Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial (2014) 0.76
Modulation of stroke risk in chronic kidney disease. Clin Kidney J (2015) 0.76
Estimation of Drug Effectiveness by Modeling Three Time-dependent Covariates: An Application to Data on Cardioprotective Medications in the Chronic Dialysis Population. Stat Biopharm Res (2014) 0.76
Treating hypertension in hemodialysis improves symptoms seemingly unrelated to volume excess. Nephrol Dial Transplant (2015) 0.75
Chapter 1: Introduction. Kidney Int Suppl (2011) (2012) 0.75
Characterizing the continuously acquired cardiovascular time series during hemodialysis, using median hybrid filter preprocessing noise reduction. Med Devices (Auckl) (2015) 0.75
Dialysis: prognostic value of blood pressure in patients on hemodialysis. Nat Rev Nephrol (2010) 0.75
Hypertension in hemodialysis patients: the role of antihypertensive medications. Am J Kidney Dis (2009) 0.75
Blood pressure in dialysis patients-look before we leap. Lancet (2009) 0.75
Blood pressure and outcome in patients on dialysis. Lancet (2009) 0.75
Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. Circ Heart Fail (2017) 0.75
Interdialytic ambulatory blood pressure in patients with intradialytic hypertension. Curr Opin Nephrol Hypertens (2012) 0.75
Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease. Semin Nephrol (2017) 0.75
Protocol of randomized control trial for effectiveness of angiotensin receptor blockers on blood pressure control among euvolemic hypertensive hemodialysis patients. Medicine (Baltimore) (2017) 0.75
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension (2016) 0.75
Meta-analysis-not proof but call for action. Hypertension (2009) 0.75
ACP Journal Club. Review: Blood pressure-lowering treatments reduce CV morbidity and mortality in patients receiving dialysis. Ann Intern Med (2009) 0.75
Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis. Clin Exp Nephrol (2015) 0.75
Blood Pressure and Risk of Cardiovascular Events in Patients on Chronic Hemodialysis: The CRIC Study (Chronic Renal Insufficiency Cohort). Hypertension (2017) 0.75
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet (1999) 37.76
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet (2003) 12.67
Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis (1998) 10.70
Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52
The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol (1998) 7.43
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis (2005) 6.31
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int (2007) 3.34
Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension (2009) 2.99
Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int (2004) 2.71
Developing a database of published reports of randomised clinical trials in pain research. Pain (1996) 2.40
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis (2008) 2.39
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med (2003) 2.21
Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Nephrol Dial Transplant (2006) 2.11
Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis (2008) 2.01
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens (2007) 2.01
Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol (2003) 1.89
Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int (2006) 1.74
Blood pressure and mortality risk on peritoneal dialysis. Am J Kidney Dis (2008) 1.68
Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol (2006) 1.67
Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol (2006) 1.61
Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol (2004) 1.48
Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol (2007) 1.31
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant (2008) 1.23
Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int (2007) 1.09
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med (2012) 11.83
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10
Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med (2009) 9.77
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int (2004) 6.32
A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med (2004) 6.26
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23
Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet (2013) 6.19
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA (2007) 6.02
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med (2015) 5.86
Chronic diseases now a leading cause of death in rural India--mortality data from the Andhra Pradesh Rural Health Initiative. Int J Epidemiol (2006) 5.60
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med (2003) 5.47
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol (2008) 5.40
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology (2005) 5.17
Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery: a randomized trial. JAMA (2002) 5.06
Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med (2005) 5.02
Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA (2008) 4.83
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82
Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension (2003) 4.71
A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med (2003) 4.52
Prognosis and prognostic research: what, why, and how? BMJ (2009) 4.46
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med (2014) 3.81
Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.78
Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med (2010) 3.70
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA (2012) 3.67
Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J (2005) 3.58
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med (2005) 3.44
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35
Population Health Metrics Research Consortium gold standard verbal autopsy validation study: design, implementation, and development of analysis datasets. Popul Health Metr (2011) 3.21
The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil (2010) 3.20
Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension (2011) 3.11
Risk prediction models: II. External validation, model updating, and impact assessment. Heart (2012) 3.05
Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med (2003) 3.02
How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ (2008) 3.00
Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation (2005) 2.97
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab (2005) 2.89
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet (2002) 2.85
Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med (2010) 2.82
Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med (2003) 2.80
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med (2009) 2.79
Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart (2012) 2.76
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet (2007) 2.65
Cognitive outcomes 7.5 years after angioplasty compared with off-pump coronary bypass surgery. Ann Thorac Surg (2013) 2.64
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause (2006) 2.64
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Cardiovascular risk perception and evidence--practice gaps in Australian general practice (the AusHEART study). Med J Aust (2010) 2.62
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Do we need to adjudicate major clinical events? Clin Trials (2008) 2.61
Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke (2003) 2.61
Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr (2004) 2.55
Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int J Epidemiol (2007) 2.54
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
A systematic review of the impact of adherence on the effectiveness of e-therapies. J Med Internet Res (2011) 2.47
High dietary glycemic load and glycemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study. J Am Coll Cardiol (2007) 2.47
Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev (2014) 2.45
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43